Cytokinetics Inc. (NASDAQ:CYTK) shares shot up 1.4% during trading on Tuesday . The company traded as high as $11.85 and last traded at $11.65, with a volume of 207,520 shares trading hands. The stock had previously closed at $11.49.

A number of brokerages have recently commented on CYTK. FBR & Co reissued a “buy” rating on shares of Cytokinetics in a report on Monday, May 2nd. Zacks Investment Research lowered Cytokinetics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Roth Capital reissued a “buy” rating on shares of Cytokinetics in a report on Saturday, April 30th. JMP Securities reissued a “buy” rating and set a $17.00 price target on shares of Cytokinetics in a report on Tuesday. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $24.00 price target on shares of Cytokinetics in a report on Wednesday, May 25th. Eight equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $18.13.

The firm’s 50-day moving average is $9.62 and its 200 day moving average is $8.00. The stock’s market capitalization is $463.70 million.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. Equities analysts forecast that Cytokinetics Inc. will post ($1.32) EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP boosted its stake in shares of Cytokinetics by 532.5% in the fourth quarter. GSA Capital Partners LLP now owns 117,931 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 99,287 shares during the last quarter. Matarin Capital Management LLC purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $2,512,000. Finally, Russell Frank Co purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $4,719,000.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.